Kevin F Kuo1, Rachel Hunter-Merrill2, Roman Gulati2, Suzanne P Hall3, Teresa E Gambol3, Celestia S Higano3, Evan Y Yu4. 1. Case Western Reserve University School of Medicine, Cleveland, OH. 2. Fred Hutchinson Cancer Research Center, Biostatistics and Biomathematics Program, Public Health Sciences Division, Seattle, WA. 3. University of Washington/Fred Hutchinson Cancer Research Center, Department of Medicine, Division of Oncology, Seattle, WA. 4. University of Washington/Fred Hutchinson Cancer Research Center, Department of Medicine, Division of Oncology, Seattle, WA. Electronic address: evanyu@u.washington.edu.
Abstract
BACKGROUND: Intermittent androgen deprivation (IAD) represents an alternative to continuous AD with quality-of-life benefit and no evidence of inferior overall survival for nonmetastatic prostate cancer. Early markers of prognosis for men treated with IAD have not been described. PATIENTS AND METHODS: Men with nonmetastatic prostate cancer were treated with 9 months of leuprolide and flutamide followed by a variable off-treatment interval; AD was resumed when prostate specific antigen (PSA) reached a prespecified value (1 ng/mL, radical prostatectomy; 4 ng/mL, intact prostate). Cycles were repeated until castration resistance (marking the advent of castration-resistant prostate cancer [CRPC]), defined as 2 PSA rises with testosterone (T) ≤ 50 ng/dL. Kinetics and relationships of PSA and T levels were evaluated, with a focus on times to rise in each level, during the first off-treatment interval. Associations with CRPC and prostate cancer mortality were estimated using Cox proportional hazards models controlling for age and Gleason score. RESULTS: Each 30-day increase in time to PSA rise was associated with a 21% reduction in the risk of developing CRPC (95% CI, 3%-36%; P = .02). Longer time (≥ 60 days) to PSA rise after rise to T > 50 ng/dL was associated with a 71% reduction in the risk of developing CRPC (95% CI, 92% reduction to 2% inflation; P = .05). Time to first T > 50 ng/dL and PSA doubling time were not prognostic for progression to CRPC. No time interval was prognostic for prostate cancer mortality. CONCLUSION: During the first off-treatment interval of IAD, longer times to PSA rise overall and after T > 50 ng/dL were associated with reduced risk of developing CRPC.
BACKGROUND: Intermittent androgen deprivation (IAD) represents an alternative to continuous AD with quality-of-life benefit and no evidence of inferior overall survival for nonmetastatic prostate cancer. Early markers of prognosis for men treated with IAD have not been described. PATIENTS AND METHODS: Men with nonmetastatic prostate cancer were treated with 9 months of leuprolide and flutamide followed by a variable off-treatment interval; AD was resumed when prostate specific antigen (PSA) reached a prespecified value (1 ng/mL, radical prostatectomy; 4 ng/mL, intact prostate). Cycles were repeated until castration resistance (marking the advent of castration-resistant prostate cancer [CRPC]), defined as 2 PSA rises with testosterone (T) ≤ 50 ng/dL. Kinetics and relationships of PSA and T levels were evaluated, with a focus on times to rise in each level, during the first off-treatment interval. Associations with CRPC and prostate cancer mortality were estimated using Cox proportional hazards models controlling for age and Gleason score. RESULTS: Each 30-day increase in time to PSA rise was associated with a 21% reduction in the risk of developing CRPC (95% CI, 3%-36%; P = .02). Longer time (≥ 60 days) to PSA rise after rise to T > 50 ng/dL was associated with a 71% reduction in the risk of developing CRPC (95% CI, 92% reduction to 2% inflation; P = .05). Time to first T > 50 ng/dL and PSA doubling time were not prognostic for progression to CRPC. No time interval was prognostic for prostate cancer mortality. CONCLUSION: During the first off-treatment interval of IAD, longer times to PSA rise overall and after T > 50 ng/dL were associated with reduced risk of developing CRPC.
Authors: Evan Y Yu; Roman Gulati; Donatello Telesca; Peter Jiang; Stephen Tam; Kenneth J Russell; Peter S Nelson; Ruth D Etzioni; Celestia S Higano Journal: J Clin Oncol Date: 2010-04-26 Impact factor: 44.544
Authors: Juanita M Crook; Christopher J O'Callaghan; Graeme Duncan; David P Dearnaley; Celestia S Higano; Eric M Horwitz; Eliot Frymire; Shawn Malone; Joseph Chin; Abdenour Nabid; Padraig Warde; Thomas Corbett; Steve Angyalfi; S Larry Goldenberg; Mary K Gospodarowicz; Fred Saad; John P Logue; Emma Hall; Paul F Schellhammer; Keyue Ding; Laurence Klotz Journal: N Engl J Med Date: 2012-09-06 Impact factor: 91.245
Authors: Evan Y Yu; Kevin F Kuo; Roman Gulati; Shu Chen; Teresa E Gambol; Suzanne P Hall; Peter Y Jiang; Peggy Pitzel; Celestia S Higano Journal: J Clin Oncol Date: 2012-04-09 Impact factor: 44.544
Authors: Andrew J Stephenson; Shahrokh F Shariat; Michael J Zelefsky; Michael W Kattan; E Brian Butler; Bin S Teh; Eric A Klein; Patrick A Kupelian; Claus G Roehrborn; David A Pistenmaa; Heather D Pacholke; Stanley L Liauw; Matthew S Katz; Steven A Leibel; Peter T Scardino; Kevin M Slawin Journal: JAMA Date: 2004-03-17 Impact factor: 56.272
Authors: Jean de Leval; Philippe Boca; Enis Yousef; Hubert Nicolas; Michel Jeukenne; Laurence Seidel; Christian Bouffioux; Luc Coppens; Pierre Bonnet; Robert Andrianne; David Wlatregny Journal: Clin Prostate Cancer Date: 2002-12
Authors: Daniel M Lim; Roman Gulati; Serge Aleshin-Guendel; Agnes Gawne; Jonathan T Wingate; Heather H Cheng; Ruth Etzioni; Evan Y Yu Journal: Prostate Date: 2018-07-10 Impact factor: 4.104
Authors: Maja Marklund; Niklas Schultz; Stefanie Friedrich; Emelie Berglund; Firas Tarish; Anna Tanoglidi; Yao Liu; Ludvig Bergenstråhle; Andrew Erickson; Thomas Helleday; Alastair D Lamb; Erik Sonnhammer; Joakim Lundeberg Journal: Nat Commun Date: 2022-09-17 Impact factor: 17.694